Low levels of Vitamin D have been shown to be associated with a higher risk of having a cardiac event, like a heart attack or stroke. For this… read more.
Food allergies can quickly turn a casual meal into a life-threatening situation. Anaphylaxis – a severe allergic reaction that may include a skin rash, nausea, vomiting, difficulty breathing,… read more.
The FDA approved Eli Lilly and Company’s Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1… read more.
The trend among younger children to frequently drink caffeinated soda may indicate higher risk of alcohol consumption in the future, new research suggests. In a study of over… read more.
Cigarette style graphic warning labels could reduce people’s meat consumption, according to new research published today (1 November). The study suggests the use of warning labels on meat… read more.
Online grocery carts tend to include less variety and fewer fruits and vegetables than those in a trip to a brick-and-mortar supermarket – but online shoppers are less… read more.
Curbing carbon emissions and eating healthier may both start at the dinner table. According to a new study co-authored by a Tulane University researcher and published in the journal Nature… read more.
A phase 3 clinical trial evaluating the injectable prescription medication tirzepatide, showed an additional 21.1% weight loss after intensive lifestyle intervention in adults with obesity or who were… read more.
STEP-HFpEF was a randomised, controlled trial designed to find out whether semaglutide for 52 weeks could improve heart failure symptoms and physical function in obese, non-diabetic patients with… read more.
The results of the STEP-HFpEF trial point towards routine use of GLP-1 agonists in heart failure but this has to be balanced against conflicting guidelines and cost pressures… read more.
The results of the STEP-HFpEF trial showed statistically significant benefits “across the board” and these benefits were not due to weight loss alone, according to Vicky Ruszala, Specialist… read more.
STEP-HFpEF was a randomised, controlled trial designed to find out whether semaglutide for 52 weeks could improve heart failure symptoms and physical function in obese, non-diabetic patients with… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
